
MORPHOSYS AG (DELISTED)
Action · DE0006632003 · 663200 (XETR)
Pas de cours
n/a
Performance
Jour | Semaine | Mois | 3 mois | 6 mois | 1 an | 5 ans |
---|---|---|---|---|---|---|
- | - | - | - | 0,00 % | 0,52 % | -39,39 % |
Profil de l'entreprise pour MORPHOSYS AG Action
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
Fonds investis
Les fonds suivants ont investi dans : MORPHOSYS AG investi :
Fonds | Vol. en millions 3,72 | Part (%) 1,18 % |
Fonds | Vol. en millions 12.878,53 | Part (%) 1,18 % |
Fonds | Vol. en millions 6.502,84 | Part (%) 0,51 % |
Fonds | Vol. en millions 12,61 | Part (%) 0,46 % |
Fonds | Vol. en millions 2.364,24 | Part (%) 0,28 % |
Données de l'entreprise
Nom MORPHOSYS AG
Société MorphoSys AG
Site web
https://www.morphosys.com
Marché d'origine
XETRA

WKN 663200
ISIN DE0006632003
Type de titre Action
Secteur Healthcare
Industrie Biotechnology
PDG Mr. Arkadius Pichota M.B.A., Ph.D.
Capitalisation boursière 3 Mrd.
Pays Allemagne
Devise EUR
Employés 0,5 T
Adresse Semmelweisstrasse 7, 82152 Planegg
Date d'introduction en bourse 1999-03-10
Symboles boursiers
Nom | Symbole |
---|---|
Frankfurt | MOR.F |
XETRA | MOR.DE |
Autres actions
Les investisseurs qui détiennent MORPHOSYS AG ont également les actions suivantes dans leur portefeuille :
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles.
Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.